Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction
View Full Paper
Ask AI
Bookmark
Share
Key result
SGLT2i emerge as effective pharmacological therapies improving clinical outcomes in HFmrEF and HFpEF.
Why the study?
Earlier landmark heart failure trials focused on HFrEF, and dedicated clinical trials determining therapeutic modalities for HFmrEF are still lacking.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports SGLT2 inhibitor use in HFmrEF/HFpEF; leaves open dedicated randomized trials for HFmrEF.
Structured PICO
P
Population
Patients with heart failure with mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF)
I
Intervention
Pharmacological therapies (including SGLT2 inhibitors, ARNIs, MRAs, ARBs, beta-blockers) and device therapies
This review highlights the evolution of HFmrEF and HFpEF definitions and summarizes the emerging evidence for therapies like SGLT2 inhibitors and ARNIs across the higher LVEF spectrum.
Limitations
- Lack of dedicated clinical trials specifically for HFmrEF, with most evidence extrapolated from subgroup analyses of HFpEF trials.
- Inherent interobserver variability of echocardiography interpretation can lead to variation in LVEF measurement and misclassification.
Cite This Study
Talha et al. (2022) conducted a review in Heart failure with mildly reduced and preserved ejection fraction. Pharmacological therapies (e.g., SGLT2 inhibitors, ARNIs, ARBs) was evaluated. Pharmacological therapies, particularly sodium-glucose cotransporter-2 inhibitors, have emerged as effective treatments that improve clinical outcomes in patients with heart failure with mildly reduced and preserved ejection fraction.
Topics
View Full Paper
Ask AI
Bookmark
Share